EGFR Amplification

Loading variant…

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Barrett Adenocarcinoma1
EGFR Amplification	(prognostic)	Prognostic	B	Supports Poor Outcome	3	accepted	EID470 In patients with Barrett's adenocarcinoma, those with amplification of EGFR had shorter disease-specific survial. PMID 20840671 · Marx et al., 2010 · Open in CIViC	civic
Cervical Squamous Cell Carcinoma1
EGFR Amplification	(prognostic)	Prognostic	B	Supports Poor Outcome	3	accepted	EID471 In patients with cervical squamous cell carcinoma, those with gene amplification of EGFR had worse overall survival. PMID 21730982 · Iida et al., 2011 · Open in CIViC	civic

Molecular profile

Therapy

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

Barrett Adenocarcinoma1

EGFR Amplification

(prognostic)

Prognostic

Supports Poor Outcome

accepted

EID470

In patients with Barrett's adenocarcinoma, those with amplification of EGFR had shorter disease-specific survial.

PMID 20840671 · Marx et al., 2010 · Open in CIViC

civic

Cervical Squamous Cell Carcinoma1

EGFR Amplification

(prognostic)

Prognostic

Supports Poor Outcome

accepted

EID471

In patients with cervical squamous cell carcinoma, those with gene amplification of EGFR had worse overall survival.

PMID 21730982 · Iida et al., 2011 · Open in CIViC

civic

Gastric Adenocarcinoma2
EGFR Amplification	Cetuximab	Predictive	B	Supports Sensitivity Response	3	submitted	EID6927 This retrospective analysis of a Phase 2 trial shows significant association between increased EGFR gene copy number (≥ 4.0) and overall survival (OS) in patients with gastric and oesophago-gastric ju… (full text at CIViC) PMID 22152101 · Luber et al., 2011 · Open in CIViC	civic
EGFR Amplification AND EGFR::SEPTIN14 Fusion	(oncogenic)	Oncogenic	C	Supports Oncogenicity	2	submitted	EID11003 A case report of a 49 year old female with gastric signet ring cell carcinoma, in whom a genomic screen of cf tumour DNA revealed an EGFR::SEPT14 fusion at a VAF of 45.3%. The fusion was confirmed by … (full text at CIViC) PMID 33969073 · Kim et al., 2021 · Open in CIViC	civic

Gastric Adenocarcinoma2

EGFR Amplification

Cetuximab

Predictive

Supports Sensitivity Response

submitted

EID6927

This retrospective analysis of a Phase 2 trial shows significant association between increased EGFR gene copy number (≥ 4.0) and overall survival (OS) in patients with gastric and oesophago-gastric ju… (full text at CIViC)

PMID 22152101 · Luber et al., 2011 · Open in CIViC

civic

EGFR Amplification AND EGFR::SEPTIN14 Fusion

(oncogenic)

Oncogenic

Supports Oncogenicity

submitted

EID11003

A case report of a 49 year old female with gastric signet ring cell carcinoma, in whom a genomic screen of cf tumour DNA revealed an EGFR::SEPT14 fusion at a VAF of 45.3%. The fusion was confirmed by … (full text at CIViC)

PMID 33969073 · Kim et al., 2021 · Open in CIViC

civic

Glioblastoma4
EGFR Amplification	Talazoparib	Predictive	D	Supports Sensitivity Response	4	submitted	EID7785 Preclinical experiments with 27 GBM patient-derived cell lines showed selective sensitivity to the PARP inhibitor talazoparib in EGFR amplified samples relative to EGFR wild-type samples (p<0.0001). F… (full text at CIViC) PMID 31852834 · Wu et al., 2020 · Open in CIViC	civic
EGFR Amplification AND EGFR EGFRVIII	Afatinib	Predictive	C	Supports Sensitivity Response	2	accepted	EID773 Case report of a 58-year old patient with disease progression after radiotherapy and three temozolomide cycles. Afatinib and temozolomide led to disease regression. At last assessment 63 treatment cyc… (full text at CIViC) PMID 26423602 · Alshami et al., 2015 · Open in CIViC	civic
EGFR Amplification AND EGFR EGFRVIII AND EGFR::SEPTIN14 Fusion	(oncogenic)	Oncogenic	B	Supports Oncogenicity	3	submitted	EID11154 RNASeq data from 161 primary GBM samples and 24 glioma spheroids were analysed for gene fusion events. EGFR::SEPT14 was found to be the most common fusion event, after the well-documented FGFR3::TACC3… (full text at CIViC) PMID 23917401 · Frattini et al., 2013 · Open in CIViC	civic
EGFR Amplification AND EGFR::SEPTIN14 Fusion	(oncogenic)	Oncogenic	B	Supports Oncogenicity	2	submitted	EID11151 Seminal paper presenting the original analysis of the TCGA Glioblastoma dataset, of over 500 glioblastoma genomes. EFGR::SEPT14 fusion was found in 6 cases by WGS and confirmed by RNASeq. The fusion i… (full text at CIViC) PMID 24120142 · Brennan et al., 2013 · Open in CIViC	civic

Glioblastoma4

EGFR Amplification

Talazoparib

Predictive

Supports Sensitivity Response

submitted

EID7785

Preclinical experiments with 27 GBM patient-derived cell lines showed selective sensitivity to the PARP inhibitor talazoparib in EGFR amplified samples relative to EGFR wild-type samples (p<0.0001). F… (full text at CIViC)

PMID 31852834 · Wu et al., 2020 · Open in CIViC

civic

EGFR Amplification AND EGFR EGFRVIII

Afatinib

Predictive

Supports Sensitivity Response

accepted

EID773

Case report of a 58-year old patient with disease progression after radiotherapy and three temozolomide cycles. Afatinib and temozolomide led to disease regression. At last assessment 63 treatment cyc… (full text at CIViC)

PMID 26423602 · Alshami et al., 2015 · Open in CIViC

civic

EGFR Amplification AND EGFR EGFRVIII AND EGFR::SEPTIN14 Fusion

(oncogenic)

Oncogenic

Supports Oncogenicity

submitted

EID11154

RNASeq data from 161 primary GBM samples and 24 glioma spheroids were analysed for gene fusion events. EGFR::SEPT14 was found to be the most common fusion event, after the well-documented FGFR3::TACC3… (full text at CIViC)

PMID 23917401 · Frattini et al., 2013 · Open in CIViC

civic

EGFR Amplification AND EGFR::SEPTIN14 Fusion

(oncogenic)

Oncogenic

Supports Oncogenicity

submitted

EID11151

Seminal paper presenting the original analysis of the TCGA Glioblastoma dataset, of over 500 glioblastoma genomes. EFGR::SEPT14 fusion was found in 6 cases by WGS and confirmed by RNASeq. The fusion i… (full text at CIViC)

PMID 24120142 · Brennan et al., 2013 · Open in CIViC

civic

Head and Neck Squamous Cell Carcinoma3
EGFR Amplification	(prognostic)	Prognostic	B	Supports Poor Outcome	4	accepted	EID473 The group of 43 out of 75 tumor samples with increased copy number or amplification of EGFR as determined by FISH (FISH-positive) had worse progression-free and overall survival than FISH-negative tum… (full text at CIViC) PMID 16943533 · Chung et al., 2006 · Open in CIViC	civic
EGFR Amplification	Afatinib + Cetuximab + ErlotinibSubstitutes	Predictive	D	Does Not Support Sensitivity Response	2	submitted	EID9674 This retrospective preclinical study assessed the efficacies of cetuximab, afatinib, and erlotinib towards head and neck squamous cell carcinoma (HNSCC) & esophageal squamous cell carcinoma (ESCC) cel… (full text at CIViC) PMID 27207775 · Nakamura et al., 2016 · Open in CIViC	civic
EGFR Amplification	Cetuximab + Fluorouracil + Platinum CompoundCombination	Predictive	B	Does Not Support Sensitivity Response	4	accepted	EID691 EGFR amplification was not a predictor of response to cetuximab/5-FU/platinum in patients with recurrent or metastatic HNSSC from the EXTREME study. PMID 21048039 · Licitra et al., 2011 · Open in CIViC	civic

Head and Neck Squamous Cell Carcinoma3

EGFR Amplification

(prognostic)

Prognostic

Supports Poor Outcome

accepted

EID473

The group of 43 out of 75 tumor samples with increased copy number or amplification of EGFR as determined by FISH (FISH-positive) had worse progression-free and overall survival than FISH-negative tum… (full text at CIViC)

PMID 16943533 · Chung et al., 2006 · Open in CIViC

civic

EGFR Amplification

Afatinib + Cetuximab + ErlotinibSubstitutes

Predictive

Does Not Support Sensitivity Response

submitted

EID9674

This retrospective preclinical study assessed the efficacies of cetuximab, afatinib, and erlotinib towards head and neck squamous cell carcinoma (HNSCC) & esophageal squamous cell carcinoma (ESCC) cel… (full text at CIViC)

PMID 27207775 · Nakamura et al., 2016 · Open in CIViC

civic

EGFR Amplification

Cetuximab + Fluorouracil + Platinum CompoundCombination

Predictive

Does Not Support Sensitivity Response

accepted

EID691

EGFR amplification was not a predictor of response to cetuximab/5-FU/platinum in patients with recurrent or metastatic HNSSC from the EXTREME study.

PMID 21048039 · Licitra et al., 2011 · Open in CIViC

civic

Hepatocellular Carcinoma1
EGFR Amplification OR EGFR Alteration	Lenvatinib	Predictive	B	Supports Resistance	3	submitted	EID12052 The ctDNA of 46 patients with hepatocellular carcinoma was analyzed to investigate whether EGFR alterations could lead to lenvatinib resistance. Among these patients, 16 had been treated with lenvatin… (full text at CIViC) PMID 36708791 · Lim et al., 2023 · Open in CIViC	civic

Hepatocellular Carcinoma1

EGFR Amplification OR EGFR Alteration

Lenvatinib

Predictive

Supports Resistance

submitted

EID12052

The ctDNA of 46 patients with hepatocellular carcinoma was analyzed to investigate whether EGFR alterations could lead to lenvatinib resistance. Among these patients, 16 had been treated with lenvatin… (full text at CIViC)

PMID 36708791 · Lim et al., 2023 · Open in CIViC

civic

Lung Non-Small Cell Carcinoma6
EGFR Amplification	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Predictive	B	Supports Sensitivity Response	4	accepted	EID948 A meta-analysis of EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment was performed. In total, 20 (1689 patients, 594 with increased gene copy n… (full text at CIViC) PMID 20826716 · Dahabreh et al., 2011 · Open in CIViC	civic
EGFR Amplification	Erlotinib	Predictive	B	Supports Sensitivity Response	4	submitted	EID7802 Study was a Phase 3 clinical trial of erlotinib in non-small cell lung cancer patients who has progressed after standard chemotherapy. Study found significantly increased survival time for patients… (full text at CIViC) PMID 16014883 · Tsao et al., 2005 · Open in CIViC	civic
EGFR Amplification	Erlotinib + GefitinibSubstitutes	Predictive	B	Supports Sensitivity Response	4	accepted	EID5924 The result of the analysis found that EGFR gene copy number was associated with increased OS and PFS, supporting the idea that EGFR gene copy number is a biomarker for response to EGFR-TKI therapy in … (full text at CIViC) PMID 20826716 · Dahabreh et al., 2011 · Open in CIViC	civic
EGFR Amplification	Erlotinib + GefitinibSubstitutes	Predictive	B	Supports Sensitivity Response	4	accepted	EID5925 Among TKI-treated patients, increased EGFR gene copy number appears to be associated with improved survival outcomes. PMID 27664271 · Zhang et al., 2017 · Open in CIViC	civic
EGFR Amplification	Erlotinib + GefitinibSubstitutes	Predictive	B	Does Not Support Sensitivity Response	2	accepted	EID977 In 290 patients with advanced NSCLC, 177 of which were treated with EGFR TKI (erlotinib or gefitinib). EGFR amplification (Multiplex ligation-dependent probe amplification; MLPA) and Mutation (PCR) we… (full text at CIViC) PMID 26722081 · Fiala et al., 2016 · Open in CIViC	civic
EGFR Amplification	Osimertinib + RociletinibSubstitutes	Predictive	D	Supports Resistance	3	accepted	EID3015 Evidence of wild-type allele-mediated resistance, a novel concept of acquired resistance in response to mutation-selective inhibitor therapy in cancer treatment. This study reports that the Src-AKT pa… (full text at CIViC) PMID 28202511 · Nukaga et al., 2017 · Open in CIViC	civic

Lung Non-Small Cell Carcinoma6

EGFR Amplification

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

Predictive

Supports Sensitivity Response

accepted

EID948

A meta-analysis of EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment was performed. In total, 20 (1689 patients, 594 with increased gene copy n… (full text at CIViC)

PMID 20826716 · Dahabreh et al., 2011 · Open in CIViC

civic

EGFR Amplification

Erlotinib

Predictive

Supports Sensitivity Response

submitted

EID7802

Study was a Phase 3 clinical trial of erlotinib in non-small cell lung cancer patients who has progressed after standard chemotherapy. Study found significantly increased survival time for patients… (full text at CIViC)

PMID 16014883 · Tsao et al., 2005 · Open in CIViC

civic

EGFR Amplification

Erlotinib + GefitinibSubstitutes

Predictive

Supports Sensitivity Response

accepted

EID5924

The result of the analysis found that EGFR gene copy number was associated with increased OS and PFS, supporting the idea that EGFR gene copy number is a biomarker for response to EGFR-TKI therapy in … (full text at CIViC)

PMID 20826716 · Dahabreh et al., 2011 · Open in CIViC

civic

EGFR Amplification

Erlotinib + GefitinibSubstitutes

Predictive

Supports Sensitivity Response

accepted

EID5925

Among TKI-treated patients, increased EGFR gene copy number appears to be associated with improved survival outcomes.

PMID 27664271 · Zhang et al., 2017 · Open in CIViC

civic

EGFR Amplification

Erlotinib + GefitinibSubstitutes

Predictive

Does Not Support Sensitivity Response

accepted

EID977

In 290 patients with advanced NSCLC, 177 of which were treated with EGFR TKI (erlotinib or gefitinib). EGFR amplification (Multiplex ligation-dependent probe amplification; MLPA) and Mutation (PCR) we… (full text at CIViC)

PMID 26722081 · Fiala et al., 2016 · Open in CIViC

civic

EGFR Amplification

Osimertinib + RociletinibSubstitutes

Predictive

Supports Resistance

accepted

EID3015

Evidence of wild-type allele-mediated resistance, a novel concept of acquired resistance in response to mutation-selective inhibitor therapy in cancer treatment. This study reports that the Src-AKT pa… (full text at CIViC)

PMID 28202511 · Nukaga et al., 2017 · Open in CIViC

civic

Malignant Colorectal Neoplasm2
EGFR Amplification	Cetuximab	Predictive	B	Supports Sensitivity Response	3	accepted	EID911 87 patients with metastatic colorectal cancer treated with cetuximab were retrospectively analyzed for EGFR amplifications by FISH. In multivariate analysis, EGFR amplification predicted response and … (full text at CIViC) PMID 18794099 · Personeni et al., 2008 · Open in CIViC	civic
EGFR Amplification	Cetuximab + PanitumumabSubstitutes	Predictive	B	Supports Sensitivity Response	3	accepted	EID854 In this meta-analysis (14 studies, 1021 patients), EGFR gene copy number (GCN) was predictive of improved progression free survival (PFS) and overall survival (OS) with cetuximab or panitumumab regard… (full text at CIViC) PMID 24653627 · Shen et al., 2014 · Open in CIViC	civic

Malignant Colorectal Neoplasm2

EGFR Amplification

Cetuximab

Predictive

Supports Sensitivity Response

accepted

EID911

87 patients with metastatic colorectal cancer treated with cetuximab were retrospectively analyzed for EGFR amplifications by FISH. In multivariate analysis, EGFR amplification predicted response and … (full text at CIViC)

PMID 18794099 · Personeni et al., 2008 · Open in CIViC

civic

EGFR Amplification

Cetuximab + PanitumumabSubstitutes

Predictive

Supports Sensitivity Response

accepted

EID854

In this meta-analysis (14 studies, 1021 patients), EGFR gene copy number (GCN) was predictive of improved progression free survival (PFS) and overall survival (OS) with cetuximab or panitumumab regard… (full text at CIViC)

PMID 24653627 · Shen et al., 2014 · Open in CIViC

civic

Malignant Gastric Neoplasm1
EGFR Amplification OR MET Amplification	(prognostic)	Prognostic	B	Supports Poor Outcome	3	submitted	EID11453 A total of 114 patients with gastric cancer were subject to genomic testing for amplified genes in this retrospective study. There were 4 MET amplifications, 3 EGFR amplifications, and 4 HER2 amplific… (full text at CIViC) PMID 22042947 · Lennerz et al., 2011 · Open in CIViC	civic

Malignant Gastric Neoplasm1

EGFR Amplification OR MET Amplification

(prognostic)

Prognostic

Supports Poor Outcome

submitted

EID11453

A total of 114 patients with gastric cancer were subject to genomic testing for amplified genes in this retrospective study. There were 4 MET amplifications, 3 EGFR amplifications, and 4 HER2 amplific… (full text at CIViC)

PMID 22042947 · Lennerz et al., 2011 · Open in CIViC

civic

Malignant Glioma1
EGFR Amplification OR EGFR VIII	Osimertinib	Predictive	C	Supports Sensitivity Response	2	submitted	EID12694 In a single-center retrospective review of recurrent malignant gliomas with EGFR alterations (n = 6, 2 GBM), osimertinib showed a manageable safety profile with thrombocytopenia in 2 patients (grade 2… (full text at CIViC) PMID 35601813 · Abousaud et al., 2021 · Open in CIViC	civic

Malignant Glioma1

EGFR Amplification OR EGFR VIII

Osimertinib

Predictive

Supports Sensitivity Response

submitted

EID12694

In a single-center retrospective review of recurrent malignant gliomas with EGFR alterations (n = 6, 2 GBM), osimertinib showed a manageable safety profile with thrombocytopenia in 2 patients (grade 2… (full text at CIViC)

PMID 35601813 · Abousaud et al., 2021 · Open in CIViC

civic

Evidence by cancer (23 items)

Clinical significance (0)